Bjarnadóttir Ragnheidur I, Tuppurainen Marjo, Killick Stephen R
Department of Obstetrics and Gynecology, landspítalinn, Rekjavik, Iceland.
Am J Obstet Gynecol. 2002 Mar;186(3):389-95. doi: 10.1067/mob.2002.121103.
The purpose of this study was to compare cycle control and tolerability of the NuvaRing (NV Organon, Oss, The Netherlands), a novel combined contraceptive vaginal ring, with a standard combined oral contraceptive pill.
Healthy women aged 18 to 40 years who requested contraception received either NuvaRing or a combined oral contraceptive containing 30 microg ethinyl estradiol and 150 microg levonorgestrel for 6 cycles in 3 similarly designed studies. Each cycle comprised 3 weeks of ring or pill use, followed by 1 ring- or pill-free week.
Two hundred forty-seven women began the studies, 121 women with NuvaRing and 126 women with the combined oral contraceptive. Withdrawal bleeding occurred in virtually all cycles in both groups. In the NuvaRing groups, the incidence of irregular bleeding was < or =5% in all cycles; this was lower than the combined oral contraceptive groups (5.4%-38.8%). Furthermore, the incidence of a normal intended bleeding pattern was significantly higher in the NuvaRing groups than in the combined oral contraceptive groups (P <.01). Both contraceptives were well tolerated.
NuvaRing has excellent cycle control and is well tolerated.
本研究旨在比较新型复方避孕阴道环NuvaRing（NV Organon公司，荷兰奥斯）与标准复方口服避孕药的周期控制情况和耐受性。
在3项设计相似的研究中，18至40岁要求避孕的健康女性接受NuvaRing或含30微克炔雌醇和150微克左炔诺孕酮的复方口服避孕药，为期6个周期。每个周期包括使用阴道环或口服避孕药3周，随后是1周不使用阴道环或口服避孕药。
247名女性开始参与研究，其中121名使用NuvaRing，126名使用复方口服避孕药。两组几乎所有周期均出现撤退性出血。在使用NuvaRing的组中，所有周期不规则出血的发生率≤5%；这低于复方口服避孕药组（5.4%-38.8%）。此外，使用NuvaRing的组正常预期出血模式的发生率显著高于复方口服避孕药组（P<.01）。两种避孕药耐受性均良好。
NuvaRing具有出色的周期控制能力且耐受性良好。
